title: Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma.
abstract: BACKGROUND
  In 5 to 10% of adult patients with asthma, aspirin (acetylsalicylic acid [ASA]) and most other nonsteroidal anti-inflammatory drugs (NSAIDs) precipitate acute asthmatic attacks. Therefore, choosing an alternative anti-inflammatory agent for patients with adverse reactions to an NSAID is a common problem in clinical practice. The discoveries that cyclooxygenase (COX)-2 is an inducible form of COX that is involved in inflammation and that COX-1 is the major isoform responsible for the production of prostaglandins have provided a reasonable basis for the development of specific COX-2 inhibitors as a new class of anti-inflammatory agents.
  
  
  OBJECTIVE
  The purpose of this study was to demonstrate that rofecoxib, a specific inhibitor of COX-2, does not cause asthmatic attacks in patients with ASA and/or other NSAID-induced asthma.
  
  
  METHODS
  We studied 40 patients, all of whom had experienced asthma induced by at least two different NSAIDs. The patients were challenged in a single-blind manner with different doses of rofecoxib on 3 different days, until either the therapeutic dose of 25 mg or intolerance was reached. Each patient was rechallenged with 25 mg of rofecoxib 7 days later if no evidence of intolerance had been observed previously.
  
  
  RESULTS
  Rofecoxib, 25 mg, was proven to be well tolerated in all 40 patients with ASA-induced and NSAID-induced asthma.
  
  
  CONCLUSIONS
  Our study appears to demonstrate that rofecoxib is a suitable NSAID for treatment of patients with ASA and/or other NSAID-induced asthma.
authors.affiliation: Department of Allergy, Hospital Ramón y Cajal, Madrid, Spain.
authors.forename: Cristina
authors.initials: C
authors.lastname: Martín-García
authors.forename: Miguel
authors.initials: M
authors.lastname: Hinojosa
authors.forename: Pilar
authors.initials: P
authors.lastname: Berges
authors.forename: Encarnación
authors.initials: E
authors.lastname: Camacho
authors.forename: Rosa
authors.initials: R
authors.lastname: García-Rodriguez
authors.forename: Teresa
authors.initials: T
authors.lastname: Alfaya
authors.forename: Alberto
authors.initials: A
authors.lastname: Iscar
mesh_terms: D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001241:Aspirin / Q000009:adverse effects*; D001249:Asthma / Q000139:chemically induced*; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016037:Single-Blind Method; D013450:Sulfones
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib; D001241:Aspirin